Tarsons Products cash PAT up 18% in Q1FY27, exports rebound 29%
Tarsons Products reported Q1FY27 consolidated revenue of ₹110.2 crore, up 21% YoY, with exports growing 29%. Cash PAT rose 18% to ₹25.6 crore, though net profit turned negative due to higher depreciation and interest costs from new CAPEX. Gross debt is ₹380 crore, with plans to reduce it by ₹40-50 crore annually. New facilities at Panchla and Amta are ramping up, expected to contribute significantly to revenue from FY28 onwards.
*this image is generated using AI for illustrative purposes only.
Tarsons Products Limited reported a 21% year-on-year revenue growth to ₹110.2 crore for the consolidated quarter ended June 30, 2026 (Q1FY27), driven by strong domestic demand and a rebound in exports. Despite a net loss of ₹1.4 crore due to higher raw material costs and expenses from new manufacturing facilities, the company’s Cash Profit After Tax (PAT) grew 18% to ₹25.6 crore, signaling underlying operational resilience.
The results were disclosed in an investor presentation filed with the Bombay Stock Exchange (BSE) and the National Stock Exchange of India (NSE) on August 11, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing provides detailed insights into the financial performance and strategic initiatives undertaken during the quarter.
Financial Performance Highlights
Consolidated revenue from operations stood at ₹110.2 crore in Q1FY27, compared to ₹91.4 crore in the corresponding quarter of the previous year (Q1FY26). The growth was broad-based, with domestic business delivering 17% year-on-year growth supported by a revival in demand across product categories. Exports rebounded strongly, growing 29% year-on-year following geopolitical tensions that impacted the previous quarter.
| Metric | Q1FY27 | Q1FY26 | Change |
|---|---|---|---|
| Consolidated Revenue | ₹110.2 cr | ₹91.4 cr | +21% |
| Standalone Revenue | ₹86.0 cr | N/A | +21% |
| Cash PAT | ₹25.6 cr | N/A | +18% |
| Net PAT | -₹1.4 cr | N/A | Loss |
Standalone revenue also grew 21% to ₹86 crore, marking the highest ever Q1 standalone revenue for the company. However, margins were pressured by increased raw material prices stemming from supply chain disruptions and expenses related to the new Panchla and Amta facilities. Key input costs rose between 25% and 50%, impacting gross margins. Standalone gross margin stood at 67.1%, while consolidated EBITDA was ₹26 crore with a margin of 23.6%.
Operational Updates and Strategic Outlook
Aryan Sehgal, Promoter and Whole Time Director, attributed the growth to deeper customer penetration and improving underlying demand. He noted that while the Amta facility has commenced commercial supplies, the cell culture lines at the Panchla facility are expected to be commissioned towards the end of Q2FY27. This expansion aims to address evolving customer needs and increase the addressable market.
The company continues to invest in automation and capacity expansion to strengthen its competitive positioning. With over four decades of brand equity, Tarsons remains focused on sustainable growth over the next three to five years, leveraging its wide distribution network and diverse product portfolio including consumables, reusables, and benchtop instrumentation.
Balance Sheet and Capital Allocation
During the earnings call, CFO Santosh Agarwal disclosed that the company’s gross debt stands at approximately ₹380 crore, with net debt around ₹330-340 crore. The company expects to reduce debt by ₹40-50 crore year-on-year through loan repayments. Depreciation for the full year is projected to peak at ₹105-110 crore as capital work in progress (CWIP) of ₹160 crore is capitalized. Interest costs are expected to remain stable at a run rate of ₹20 crore per year in FY27 before declining in FY28.
What the Numbers Show
The divergence between the negative Net PAT and the positive, growing Cash PAT highlights the impact of non-cash items such as accelerated depreciation and finance costs associated with capital expenditure on new facilities. This suggests that core operational cash generation remains robust despite short-term profitability pressures from expansion-related investments. The strong rebound in exports, coupled with domestic growth, indicates a recovery in demand across both geographies, offsetting the margin pressure from rising raw material costs.
Historical Stock Returns for Tarsons Products
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.10% | -4.15% | +10.79% | +86.80% | +7.91% | -57.66% |
How will the commissioning of the Panchla facility's cell culture lines in Q2FY27 impact Tarsons' gross margins and addressable market share in the biotech sector?
Given the 25-50% rise in key input costs, what specific hedging strategies or supply chain diversifications is Tarsons implementing to protect margins in FY27?
With net debt projected to decrease by ₹40-50 crore annually, how might Tarsons' improved debt-to-equity ratio influence its cost of capital and future expansion plans?
15
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
